Invatec is an associated company of Bioprospect
Invatec has developed the worlds first quantitative analysis for depression.
This patented innovative unique technology is non intrusive, quick, objective, decisive and will revolutionise the diagnosis and treatment of mental health.
Over 10 years of research into the relationship between the autonomic nervous system, psychological state and heart rate activity.
Depression is estimated to cost US economy US$83 billion a year with the cost in Australia estimated at $15 billion annually.
Complete role out of the technology is projected for 2014/15.